Please assess the completion status of the following clinical trial:

Trial Title: A Study of Galunisertib in Participants With Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of MDS based on the World Health Organization (WHO) criteria~* Participants with 5q deletions are allowed only if they have failed or are intolerant of lenalidomide treatment~* Participants must have a Revised International Prognostic Scoring System (IPSS-R) category of very low-, low-, or intermediate-risk disease~* In the 8 weeks prior to registration, participants in phase 2 should have anemia with Hb ≤10.0 g/dL (based on the average of 2 baseline measurements and untransfused for at least 1 week) with or without red blood cell (RBC) transfusion dependence confirmed for a minimum of 8 weeks before enrollment~* For phase 3, participants should have anemia with RBC transfusion dependence confirmed within 8 weeks before enrollment~* Performance status ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale~Exclusion Criteria:~* No history of moderate or severe cardiac disease~* No prior history of acute myeloid leukemia (AML)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase (ph) 2: Galunisertib + BSC (Type: EXPERIMENTAL): Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
- Ph 3: Placebo + BSC (Type: PLACEBO_COMPARATOR): Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
- Ph 3: Galunisertib + BSC (Type: EXPERIMENTAL): 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).